Le Lézard
Classified in: Health
Subjects: TRI, FDA, FVT

Nashville surgeon to be the first in Tennessee to surgically implant the first and only trifocal lens in the U.S.


NASHVILLE, Tenn., Aug. 30, 2019 /PRNewswire/ -- Jeffrey D. Horn, MD, owner of Vision For Life in Nashville, is set to be the first to surgically implant the new FDA approved PanOptix Trifocal Intraocular Lens on Wednesday, Sept. 4, and you are invited to the procedure and interview the surgeon and the patient pre- and post-operatively.

A limited number of media will also be granted access to video the procedure.

The first surgery since gaining FDA approval is slated to begin at 11 a.m. at The Eye Surgery Center of Middle Tennessee. Below is the address and the tentative interview schedule. Times may vary as it's a busy surgery day.

210 25th Ave. N., Suite 920., Nashville, TN 37203

8 a.m. ? 8:15 a.m. ? Dr. Horn pre-op interview

8:45 a.m. ? 9:10 a.m. ? Patient pre-op interview

10:40 a.m. ? 10:55 a.m. ? Dr. Horn pre-op interview

11 a.m. ? 11:30 a.m. ? Surgery (cameras will be allowed in O.R. on a limited basis)

11:30 a.m. ? 11:45 a.m. ? Dr. Horn post-op interview

11:45 a.m. ? 12 p.m. ? Patient post-op interview

"This is an extremely exciting advancement in the treatment of cataract surgery," Horn said. "The trifocal lens corrects vision at all distances and is quite simply the best lens I have ever implanted."

The FDA approval of PanOptix was based on a pivotal study at 12 investigational sites in the U.S., including Vision For Life here in Nashville, being led by Dr. Horn.

With this single trifocal lens design, PanOptix patients demonstrated exceptional, uninterrupted vision. The results also showed high patient satisfaction with more than ninety-nine percent of PanOptix patients saying they would choose the same lens again.

According to Alcon, the manufacturer of the PanOptix lens, more than 4 million cataract surgeries are performed each year in the U.S., which is projected to increase by more than 16 percent by the end of 2024.

Cataracts are the most common age-related eye condition and the leading cause of preventable blindness. Twenty million people in the U.S. age 40 and older have cataracts, but they can be reversed with surgery. Cataracts are treated by removing the eye's cloudy natural lens and surgically replacing it with an intraocular lens or IOL. More than 98 percent of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.

"It is, quite simply, the best lens I've ever implanted." Horn said. "The results of the trial are incredible."

IF YOU WOULD LIKE TO JOIN DR. HORN ON WEDNESDAY FOR THE PANOPTIX LENS IMPLANT SURGERY, PLEASE CONTACT MATT HUDSON AT 615.482.4296 or [email protected]

CONTACT
Matt Hudson/Brass Advertising   
615.482.4296 
[email protected]

SOURCE Jeffrey D. Horn, MD Vision For Life


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...



News published on and distributed by: